Medical Training AIBiomarker-Guided Cancer Treatment
Interpret tumor profiling results and match patients to targeted therapy and immunotherapy options based on biomarker status.
What this track covers
This track covers how molecular tumor profiling, actionable biomarkers, and liquid biopsy findings inform treatment selection in oncology. It addresses reading next-generation sequencing and comprehensive genomic profiling reports, recognizing targetable alterations, and understanding when checkpoint inhibitors, targeted agents, or clinical trial referral are appropriate next steps.
What you will practice
- Interpret an NGS or comprehensive genomic profiling report for actionable alterations
- Distinguish EGFR, ALK, ROS1, BRAF, and HER2 findings that suggest targeted therapy candidacy
- Assess PD-L1 and tumor mutational burden results for immunotherapy selection
- Use ctDNA liquid biopsy results to track treatment response or emerging resistance
- Identify patients who may be candidates for basket, umbrella, or expanded access trials
Simulator scenario
A patient with newly metastatic non-small cell lung cancer presents with a genomic profiling report showing an EGFR exon 19 deletion, requiring the clinician to determine appropriate next steps in treatment sequencing.
Board question topics
- Actionable biomarker recognition in genomic profiling reports
- Selecting targeted therapy based on molecular alterations
- Immunotherapy biomarker interpretation (PD-L1, TMB)
- Liquid biopsy use in monitoring and resistance detection
Ask the tutor
The tutor only answers from licensed sources (FDA prescribing information, public guidelines and our own material) and says when it has none. Educational use only, never patient-specific advice.
Free during the beta. Sign in with your email, no password.
Start free